Lucid Diagnostics (LUCD) Stock Price, News & Analysis

Company Overview

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States. The company’s test is billed under existing procedural codes, and Lucid engages with payers to secure coverage and reimbursement. In addition to its core oral cancer test, the company is developing complementary assays and workflow enhancements aimed at broadening its diagnostic portfolio and supporting earlier intervention in head and neck malignancies.

Headquartered in the Pacific Northwest, Lucid Diagnostics began trading on the NASDAQ under the ticker LUCD in mid-2021 following a strategic reorganization and capital raise. The senior management team comprises professionals with backgrounds in in-vitro diagnostics, clinical laboratory operations and life-science commercialization. Looking ahead, Lucid is focused on expanding its sales footprint, advancing payer relationships and exploring international distribution agreements to extend access to its non-invasive oral cancer detection platform.

Key Stats

• Today's Range: $0.97 to $1.03
• 50-Day Range: $0.87 to $1.15
• 52-Week Range: $0.86 to $1.63
• Volume: 932,477 shs
• Average Volume: 1.26 million shs
• Market Capitalization: $202.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.19
• Consensus Rating: Moderate Buy

Lucid Diagnostics Stock Analysis - MarketRank™

Lucid Diagnostics scored higher than 61% of companies evaluated by MarketBeat, and ranked 268th out of 909 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lucid Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Lucid Diagnostics has a consensus price target of $4.19, representing about 312.6% upside from its current price of $1.02.

Amount of Analyst Coverage

Lucid Diagnostics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.23) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lucid Diagnostics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lucid Diagnostics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.42% of the float of Lucid Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Lucid Diagnostics has a short interest ratio ("days to cover") of 8.29.

Change versus previous month

Short interest in Lucid Diagnostics has recently increased by 11.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lucid Diagnostics does not currently pay a dividend.

Dividend Growth

Lucid Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: -0.08

News Sentiment

Lucid Diagnostics has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $245,000.00 in company stock, which represents 0.1188% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Lucid Diagnostics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $245,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

6.90% of the stock of Lucid Diagnostics is held by insiders.

Percentage Held by Institutions

74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LUCD
• CIK: 1799011
• Web: www.luciddx.com
• Phone: 212-949-4319
• Fax: N/A
• Employees: 70
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Lucid Diagnostics: $4.19
• High Price Target: $9.25
• Low Price Target: $2.00
• Potential Upside/Downside: +312.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.01 million
• Net Margins: -959.76%
• Pretax Margin: -959.76%
• Return on Equity: N/A
• Return on Assets: -119.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.33
• Quick Ratio: 1.31

Sales & Book Value

• Annual Sales: $4.71 million
• Price / Sales: 43.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.31) per share
• Price / Book: -3.27

Miscellaneous

• Outstanding Shares: 203,240,000
• Free Float: 189,220,000
• Market Cap: $206.29 million
• Optionable: No Data
• Beta: 1.08